1. Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. The Lancet 387:1094-1108, 2016.
2. Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer:A systematic review. Gynecologic Oncology, 101:520-529, 2006.
3. Soeda S, Watanabe T, Nomura S, et al. Surgical management of recurrent gynecological cancer:Complete resection is the key to longer survival. European Journal of Gynaecological Oncology, 40:28-35, 2019.
4. Höckel M, Dornhöfer N. Pelvic exenteration for gynaecological tumours. Lancet Oncol, 7:837-847, 2006.
5. Papadia A, Bellati F, Ditto A, et al. Surgical Treatment of Recurrent Endometrial Cancer:Time for a Paradigm Shift. Annals of Surgical Oncology, 22:4204-4210, 2015.
6. Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer:A phase II study. Journal of Clinical Oncology, 19: 4048-4053, 2001.
7. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer:A systematic review of Cochrane collaboration. Annals of Oncology, 18:409-420, 2007.
8. Merck Sharp & Dohme Corp. A BREAKTHROUGH THAT MAY HELP YOU FACE YOUR CANCER. 2512, 2020.
9. Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer:A review of the literature. Acta Oncologica, 28:561-566, 1989.
10. Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocrine-Related Cancer, 16:363-380, 2009.
11. Del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer:A review of the literature. Gynecologic Oncology, 127:651-661, 2012.
12. Rauh-Hain JA, Carmen, MG. Treatment for Advanced and Recurrent Endometrial Carcinoma:Combined Modalities. The Oncologist, 15:852-861, 2010.
13. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer:Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 38:1-10, 2020.
14. Chan JK, Lakomy DS, McDonald Y, et al. Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer. Gynecologic Oncology Reports, 33:100581, 2020.
15. Bristow RE, Zerbe MJ, Rosenshein NB, et al. Stage IVB endometrial carcinoma:The role of cytoreductive surgery and determinants of survival. Gynecologic Oncology, 78:85-91, 2000.